Angiotensin converting enzyme inhibitors and angiotensin receptor blockers.
作者信息
Shrimpton A J, Walker S L M, Ackland G L
机构信息
School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, UK.
William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
出版信息
BJA Educ. 2020 Nov;20(11):362-367. doi: 10.1016/j.bjae.2020.07.004. Epub 2020 Aug 27.
Abstract
摘要
相似文献
1
Angiotensin converting enzyme inhibitors and angiotensin receptor blockers.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂。
BJA Educ. 2020 Nov;20(11):362-367. doi: 10.1016/j.bjae.2020.07.004. Epub 2020 Aug 27.
2
Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.1型血管紧张素II受体阻滞剂与血管紧张素转换酶抑制剂治疗高血压的比较。
J Hypertens Suppl. 1997 Dec;15(6):S31-6. doi: 10.1097/00004872-199715066-00007.
3
A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.一项关于血管紧张素受体阻滞剂和血管紧张素转换酶抑制剂对糖尿病肾病影响的回顾性研究。
Indian J Pharmacol. 2015 Mar-Apr;47(2):148-52. doi: 10.4103/0253-7613.153420.
4
Angiotensin converting enzyme inhibitor prevents left ventricular remodelling after myocardial infarction in angiotensin II type 1 receptor knockout mice.血管紧张素转换酶抑制剂可预防1型血管紧张素II受体敲除小鼠心肌梗死后的左心室重构。
Heart. 2005 Aug;91(8):1080-5. doi: 10.1136/hrt.2004.035618.
5
Beneficial effect of replacing of angiotensin-converting enzyme inhibitor with angiotensin II antagonist for heart failure patients.对于心力衰竭患者，用血管紧张素II拮抗剂替代血管紧张素转换酶抑制剂的有益效果。
J Clin Pharm Ther. 2002 Aug;27(4):267-71. doi: 10.1046/j.1365-2710.2002.00420.x.
6
Risk of Osteoporotic Fractures With Angiotensin II Receptor Blockers Versus Angiotensin-Converting Enzyme Inhibitors in Hypertensive Community-Dwelling Elderly.社区居住的老年高血压患者中，血管紧张素II受体阻滞剂与血管紧张素转换酶抑制剂相比，发生骨质疏松性骨折的风险
J Bone Miner Res. 2014 Nov;29(11):2483-8. doi: 10.1002/jbmr.2271.
7
Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors.血管紧张素转换酶基因多态性与接受血管紧张素转换酶抑制剂治疗患者左心室肥厚消退之间的关联。
Am J Med. 1999 May;106(5):544-9. doi: 10.1016/s0002-9343(99)00067-4.
8
Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema.血管紧张素转换酶抑制剂诱发血管性水肿患者使用血管紧张素II受体阻滞剂的情况
Ann Pharmacother. 2000 Apr;34(4):526-8. doi: 10.1345/aph.19294.
9
Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study.血管紧张素 II 受体阻滞剂和 ACE（血管紧张素转换酶）抑制剂对 COVID-19 合并高血压患者病毒感染、炎症状态和临床结局的影响：一项单中心回顾性研究。
Hypertension. 2020 Jul;76(1):51-58. doi: 10.1161/HYPERTENSIONAHA.120.15143. Epub 2020 Apr 29.
本文引用的文献
1
The Endocrine Function of the Heart: Physiology and Involvements of Natriuretic Peptides and Cyclic Nucleotide Phosphodiesterases in Heart Failure.心脏的内分泌功能：利钠肽和环核苷酸磷酸二酯酶在心力衰竭中的生理学及作用
J Clin Med. 2019 Oct 21;8(10):1746. doi: 10.3390/jcm8101746.
2
The (pro)renin receptor in health and disease.在健康和疾病中的（前）肾素受体。
Nat Rev Nephrol. 2019 Nov;15(11):693-712. doi: 10.1038/s41581-019-0160-5.
3
Perioperative management of angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers: a survey of perioperative medicine practitioners.血管紧张素转换酶抑制剂和/或血管紧张素受体阻滞剂的围手术期管理：围手术期医学从业者的一项调查
PeerJ. 2018 Jun 29;6:e5061. doi: 10.7717/peerj.5061. eCollection 2018.
4
A Systematic Review of Outcomes Associated With Withholding or Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Before Noncardiac Surgery.在非心脏手术前停用或继续使用血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂相关结局的系统评价。
Anesth Analg. 2018 Sep;127(3):678-687. doi: 10.1213/ANE.0000000000002837.
5
Elevated preoperative heart rate is associated with cardiopulmonary and autonomic impairment in high-risk surgical patients.术前心率升高与高危手术患者心肺和自主神经功能损害有关。
Br J Anaesth. 2017 Jul 1;119(1):87-94. doi: 10.1093/bja/aex164.
6
Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction.射血分数降低的心力衰竭住院患者中血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂的起始、持续使用或撤药与预后
J Am Heart Assoc. 2017 Feb 11;6(2):e004675. doi: 10.1161/JAHA.116.004675.
7
Withholding versus Continuing Angiotensin-converting Enzyme Inhibitors or Angiotensin II Receptor Blockers before Noncardiac Surgery: An Analysis of the Vascular events In noncardiac Surgery patIents cOhort evaluatioN Prospective Cohort.非心脏手术前停用与继续使用血管紧张素转换酶抑制剂或血管紧张素II受体阻滞剂：非心脏手术患者队列评估前瞻性队列中的血管事件分析
Anesthesiology. 2017 Jan;126(1):16-27. doi: 10.1097/ALN.0000000000001404.
8
Mega clinical trials which have shaped the RAS intervention clinical practice.塑造了RAS干预临床实践的大型临床试验。
Ther Adv Cardiovasc Dis. 2016 Jun;10(3):133-50. doi: 10.1177/1753944716644131.
9
The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan.心力衰竭中的中性肽链内切酶途径：沙库巴曲缬沙坦应用的综述与指南
Heart. 2016 Sep 1;102(17):1342-7. doi: 10.1136/heartjnl-2014-306775. Epub 2016 May 20.
10
A Randomized Trial of Intensive versus Standard Blood-Pressure Control.强化与标准血压控制的随机试验
N Engl J Med. 2015 Nov 26;373(22):2103-16. doi: 10.1056/NEJMoa1511939. Epub 2015 Nov 9.
Zotero 插件